Patents Assigned to SDF BioPharma
  • Genetically modified stem cells
    Patent number: 12365876
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: July 25, 2023
    Date of Patent: July 22, 2025
    Assignee: SDF BioPharma
    Inventors: Gerald F. Swiss, David Kiewlich